



NCCN would like to thank the outstanding faculty who are presenting and you for attending this educational program.

We hope you find the information useful to your practice, and we encourage you to attend future NCCN educational initiatives.

Contents	Pages
Agenda	1
Accreditation Information	2 – 6
<i>Supporting Organizations</i>	3
<i>How to Claim Credit</i>	6
Disclosure Information	7 – 9
Speaker Biographies	10 – 14
Learn More about NCCN	15



Agenda

7:45 AM – 8:30 AM	Registration, Breakfast, and Exhibits
8:30 AM – 8:35 AM	Opening Remarks William J. Gradishar, MD <i>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</i>
8:35 AM – 9:20 AM	Breast Cancer Screening and Genetic Testing: Who Is at Risk and How Do We Optimize Their Care? Tuya Pal, MD <i>Vanderbilt-Ingram Cancer Center</i>
9:20 AM – 10:35 AM	Neoadjuvant/Adjuvant Treatment of Early-Stage Breast Cancer with SABCS Updates Lisa E. Flaum, MD, <i>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</i> Melissa M. McShane, MD, <i>Fox Chase Cancer Center</i> Kay T. Yeung, MD, <i>UC San Diego Moores Cancer Center</i>
10:35 AM – 10:55 AM	Break and Exhibits
10:55 AM – 11:40 AM	Updates to Radiation Therapy for Invasive Breast Cancer with SABCS Updates Bethany M. Anderson, MD <i>University of Wisconsin Carbone Cancer Center</i>
11:40 AM – 12:10 PM	Surgical Management of Invasive Breast Cancer with SABCS Updates Meghan R. Flanagan, MD, MPH <i>Fred Hutchinson Cancer Center</i>
12:10 PM – 12:40 PM	Optimizing Care for Breast Cancer-Related Lymphedema Ann Marie Flores, PT, MSPT, MA, PhD, Certified Lymphedema Therapist <i>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</i>
12:40 PM – 1:40 PM	Lunch and Exhibits
1:40 PM – 2:10 PM	Phyllodes Tumors of the Breast: Challenges in Diagnosis and Treatment Laura H. Rosenberger, MD, MS <i>Duke Cancer Institute</i>
2:10 PM – 3:25 PM	Advances in the Management of Metastatic Breast Cancer with SABCS Updates Frederick M. Howard, MD, <i>The UChicago Medicine Comprehensive Cancer Center</i> William J. Gradishar, MD, <i>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</i> Melinda L. Telli, MD, <i>Stanford Cancer Institute</i>
3:25 PM – 3:35 PM	Break
3:35 PM – 4:35 PM	Treating Toxicities of Targeted and Immune-Based Therapies Irene M. Kang, MD, <i>City of Hope National Medical Center</i> Wafa Samara, PharmD, <i>City of Hope National Medical Center</i> Kay T. Yeung, MD, <i>UC San Diego Moores Cancer Center</i>
4:35 PM	Closing Remarks William J. Gradishar, MD <i>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</i>



Accreditation Information

Program Overview

The *NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium* is a CE-certified program designed for health care professionals who provide care for patients with breast cancer. This congress offers expert insights into current recommendations of care for patients with breast cancer and highlights the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

Intended Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician associates, pharmacists, case managers, oncology data specialists, social workers, and other health care professionals who treat patients with breast cancer.

Goal of Education

The goal of the *NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium* is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:

- Summarize the current recommendations for oncology care, key updates in the NCCN Guidelines®, and clinical research updates from the 2025 SABCS and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer.
- Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with cancer and the delivery of oncology care.

Session Learning Objectives

Breast Cancer Screening and Genetic Testing: Who Is at Risk and How Do We Optimize Their Care?

- Identify recent updates and recommendations regarding eligibility for germline genetic testing in patients with breast cancer and their close blood relatives.
- Outline breast cancer risk management recommendations in carriers of breast cancer susceptibility genes.

Neoadjuvant/Adjuvant Treatment of Early-Stage Breast Cancer with SABCS Updates

- Recognize key factors that influence selection of systemic neoadjuvant/adjuvant therapy for patients with non-metastatic breast cancer.
- Discuss new and emerging treatment strategies for neoadjuvant/adjuvant treatment of non-metastatic breast cancer.

Updates to Radiation Therapy for Invasive Breast Cancer with SABCS Updates

- Develop evidence-based approaches for the use of adjuvant radiation therapy for invasive non-metastatic breast cancer.
- Discuss current and emerging radiation treatment modalities for invasive non-metastatic breast cancer.



Session Learning Objectives (continued)

Surgical Management of Invasive Breast Cancer with SABCS Updates

- Develop evidence-based approaches for selecting the optimal surgical procedure for patients with invasive non-metastatic breast cancer.
- Discuss new and emerging data in the surgical management of invasive non-metastatic breast cancer and integrate key findings into clinical practice.

Optimizing Care for Breast Cancer-Related Lymphedema

- Explain strategies for screening and early detection of lymphedema in breast cancer survivors.
- Discuss approaches for the management of lymphedema in breast cancer survivors.

Phyllodes Tumors of the Breast: Challenges in Diagnosis and Treatment

- Discuss therapeutic approaches for borderline and malignant phyllodes tumors of the breast.
- Explain strategies to reduce local recurrence in patients with phyllodes tumors of the breast.

Advances in the Management of Metastatic Breast Cancer with SABCS Updates

- Utilize evidence-based approaches to select optimal first- and subsequent-line treatment options for patients with metastatic breast cancer.
- Outline new and emerging therapeutic options for metastatic breast cancer.

Treating Toxicities of Targeted and Immune-Based Therapies

- Recognize potential adverse events associated with targeted and immune-based therapies for breast cancer.
- Discuss various approaches for the treatment of adverse events from breast cancer therapies.

CE Supporters

This activity is supported by educational grants from:

- AstraZeneca
- Lilly
- Menarini-Stemline
- Novartis
- Puma Biotechnology

This activity is supported through independent educational grants from:

- Daiichi Sankyo
- Merck & Co., Inc., Rahway, NJ, USA

Supported by a grant from Pfizer Inc.



Accreditation Information

Accreditation Statements



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians

NCCN designates this live activity for a maximum of 6.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

NCCN designates this educational activity for a maximum of 6.5 contact hours.

Pharmacists

NCCN designates this knowledge-based continuing education activity for 6.5 contact hours (0.65 CEUs) of continuing education credit. UAN: JA4008196-0000-26-016-L01-P

Physician Associates

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Social Workers

As a Jointly Accredited Organization, NCCN is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NCCN maintains responsibility for this course. Social workers completing this course receive 6.5 continuing education credits.

Case Managers

This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 6.5 CE contact hours. Activity Code: C00066011 | Approval Number: 260000065



Oncology Data Specialists

The “**NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium**” program supports 6.5 CE hours of which 4.25 hours meet the *Category A* requirement. This program has been assigned the following event number: 2025-363.



The “**NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium**” program supports 6.5 CEIP hours of which 4.25 hours meet the *Category A* requirement. This program has been assigned the following event number: 2025-363IP.

Accreditation Information

Accreditation Statements (continued)



American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.



American Board of Pathology Maintenance of Certification (MOC)

This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn up to 6.5 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.



American Board of Surgery Continuous Certification (CC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Medical Specialties (MOC)

*Through the American Board of Medical Specialties ("ABMS") ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, the **NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium** has met the requirements as a **Lifelong Learning CME Activity** (apply toward general CME requirement) by the following ABMS Member Boards:*

MOC Part II CME Activity

Medical Genetics and Genomics
Radiology

Permission to Upload Credits

For ABIM, ABPath, and ABS MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.



Accreditation Information

How to Claim CE Credit

Before claiming CE credit, please ensure that you have an NCCN account and will receive the correct type of credit.

1. Sign in at [NCCN.org/login](https://www.nccn.org/login).
 - *If you do not have an NCCN account, click Create Account.*
2. Under Account Settings, click **Edit Account** → **Profile**.
3. Verify that your **User Type** matches the type of credit that you will claim.
 - Physician/Surgeon/Oncologist: *AMA PRA Category 1 Credits™*; MOC points, if applicable*
 - Physician Associate: AAPA Category 1 CME credits
 - Pharmacist: ACPE contact hours**
 - Nurse Practitioner: ANCC contact hours
 - Clinical Nurse Specialist: ANCC contact hours
 - Nurse/Oncology Nurse: ANCC contact hours; CCM clock hours
 - Case Manager (Nurse): ANCC contact hours; CCM clock hours
 - Case Manager (Non-Nurse): CCM clock hours
 - Social Worker: ASWB continuing education credit
 - Oncology Data Specialist: NCRA CE hours
 - All Other User Types: certificate of participation
4. Scroll down and click **Save** if you make any changes.

Credit claiming will open at the conclusion of the Congress. (Friday, February 6, 2026, 4:35 PM CST.)

To claim your credits, you will need to log-in with the same email address used for program registration.

1. Log-in at education.nccn.org/breast2026.
2. Click the **Take Course** button.
3. Follow the prompts to complete the **post-test** and **evaluation** and claim your credits.

***Physicians claiming ABIM, ABPath, or ABS MOC points:** ABIM/ABPath/ABS MOC points are reported to ABIM/ABPath/ABS after you have completed the post-test and evaluation and claimed your credits. **Be sure to enter your learner/diplomate ID and date of birth when prompted in the evaluation.** Your credit cannot be reported without this information. By sharing your learner/diplomate ID and date of birth, you are giving NCCN permission to use this information/data to report your participation to ABIM/ABPath/ABS via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

****Pharmacists:** You must complete all requirements for credit by **Monday, March 23, 2026**. Continuing pharmacy education credit is reported to the CPE Monitor after you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth. Your credit cannot be reported without this information.



Disclosure Information

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose **ALL** financial relationships they have had in the past 24 months with ineligible companies. The ACCME *Standards for Integrity and Independence* require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past **24 months** are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

NCCN Staff Disclosures

None of the other planners for this educational activity have **relevant** financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty Disclosures

The faculty listed below have **no relevant financial relationships** with ineligible companies to disclose.

Bethany M. Anderson, MD
Ann Marie Flores, PT, MSPT, MA, PhD
Tuya Pal, MD
Laura H. Rosenberger, MD, MS
Wafa Samara, PharmD



Disclosure Information

Faculty Disclosures (continued)

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Meghan R. Flanagan, MD, MPH

Intuitive Surgical, Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Perimeter Medical Imaging AI: Grant/Research Support

Lisa E. Flaum, MD

AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau
Biotheranostics: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

William J. Gradishar, MD (*Congress Chair and Moderator*)

AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Carrick Therapeutics, Inc.: Scientific Advisor
Daiichi-Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor

Frederick M. Howard, MD

Leica Biosystems: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

Irene Kang, MD

AstraZeneca Pharmaceuticals LP: Consulting Fee
BioNTech: Consulting Fee
Caris Life Sciences: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Gilead Sciences, Inc. Consulting Fee
Menarini Stemline: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee

Melissa M. McShane, MD

AstraZeneca Pharmaceuticals LP: Consulting Fee

Melinda L. Telli, MD

Arvinas: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BioNTech: Grant/Research Support; Scientific Advisor
Blueprint Medicines: Scientific Advisor
Celcuity: Consulting Fee
Foresight Diagnostics: Scientific Advisor
G1 Therapeutics: Consulting Fee
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
Lilly: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Natera: Scientific Advisor



Disclosure Information

Faculty Disclosures (continued)

Melinda L. Telli, MD (continued)

Novartis Pharmaceuticals Corporation: Scientific Advisor
OncoSec Medical: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor
Summit Therapeutics: Scientific Advisor

Kay T. Yeung, MD, PhD

Alterome Therapeutics: Grant/Research Support
Arvinas: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BioFluidica: Grant/Research Support
BriaCell Therapeutics: Grant/Research Support
Dantari, Inc.: Grant/Research Support
Endeavor BioMedicines: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
Greenwich Therapeutics: Grant/Research Support
Iambic Therapeutics: Grant/Research Support
Immunomedics, Inc.: Grant/Research Support
Jazz Pharmaceuticals Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
MOMA Therapeutics: Grant/Research Support
OBI Pharma: Grant/Research Support
OnKure Therapeutics: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Poseidon Therapeutics: Grant/Research Support
Pyxis Oncology: Grant/Research Support
Regeneron Pharmaceuticals: Grant/Research Support
Regor Therapeutics: Grant/Research Support
Relay Therapeutics: Grant/Research Support
SeaGen: Grant/Research Support
Stemline Therapeutics: Grant/Research Support
Zymeworks: Grant/Research Support



Speaker Biographies



William J. Gradishar, MD, is the Betsy Bramsen Professor of Breast Oncology at the Feinberg School of Medicine at Northwestern University. Dr. Gradishar also serves as Deputy Director for the Clinical Network of the Robert H. Lurie Comprehensive Cancer Center, where he also acts as Director of the Maggie Daley Center for Women's Cancer Care. Additionally, he has served as Chair of the Annual Lynn Sage Comprehensive Breast Cancer Symposium since its inception.

Dr. Gradishar earned his medical degree from the University of Illinois Abraham School of Medicine. He later completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center and a fellowship in medical oncology at the University of Chicago. He is board-certified in internal medicine and medical oncology.

Dr. Gradishar specializes in breast cancer therapeutics, with a focus on new endocrine therapy, chemotherapy, and biologic agents. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology (ASCO). He also is a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors. Additionally, Dr. Gradishar serves as a consultant to the FDA's Oncology Drug Advisory Committee.

In addition to his professional memberships, Dr. Gradishar is an editorial board member for numerous journals, including *Journal of Clinical Oncology*, *Oncology*, *Clinical Breast Cancer*, *Journal Watch*, *European Journal of Clinical and Medical Oncology*, *Clinical Cancer Research*, and *JNCCN—Journal of the National Comprehensive Cancer Network*.

Dr. Gradishar is Chair of the NCCN Breast Cancer Panel and a member of the NCCN Breast Cancer Risk Reduction Panel. He also has participated on several committees for the NCCN Oncology Research Program.



Bethany M. Anderson, MD, is Professor in the Department of Radiation Medicine at University of Wisconsin Carbone Cancer Center. Dr. Anderson specializes in treatment of breast and gynecologic cancers. Her research is focused on partial breast irradiation, hypofractionated whole breast irradiation, MRI-guided external radiation and brachytherapy.

Dr. Anderson received her medical degree from University of Wisconsin-Madison, where she went on to complete her radiation oncology residency. She completed a fellowship in brachytherapy at Institut Gustave Roussy.

Dr. Anderson is a member of the NCCN Breast Cancer Panel and serves as the panel's radiation reviewer.



Meghan R. Flanagan, MD, MPH, is an Associate Professor of Surgery at the University of Washington and Fred Hutchinson Cancer Center, where she specializes in breast surgical oncology. She is the Program Director of the Breast Surgical Oncology Fellowship and serves as Medical Director of the UWMC–Northwest Breast Surgery Clinic.

Dr. Flanagan's research focuses on locoregional management of breast cancer, axillary surgery, invasive lobular carcinoma, and the integration of patient-reported outcomes and molecular biomarkers to inform surgical decision-making. She is an active investigator in national cooperative groups and serves on multiple national committees, including the NCCN Breast Cancer Screening and Diagnosis Panel and leadership roles within the Society of Surgical Oncology and the American Society of Breast Surgeons.

Her work has been widely published in leading surgical and oncology journals and is supported by funding from the NIH, Department of Defense, and private foundations.



Speaker Biographies



Lisa E. Flaum, MD, is an Associate Professor of Medicine in the Division of Hematology/Oncology at Northwestern University. She also serves as a member of the Robert H. Lurie Comprehensive Cancer Center's Breast Oncology Team, providing patient-centered, comprehensive care to patients at the Maggie Daley Center for Women's Cancer Care in Prentice Women's Hospital.

Dr. Flaum earned her medical degree from Georgetown University School of Medicine. She completed a residency in internal medicine at Northwestern University, where she also completed a fellowship in hematology and oncology. Dr. Flaum is board-certified in medical oncology and is a member of the American Society of Clinical Oncology.


Dr. Flaum is active in clinical research and has published numerous articles in the field of breast oncology, with a focus on endocrine therapies for breast cancer and genomic tools to guide breast cancer treatment. She has a particular interest in the treatment of young women with breast cancer.



Ann Marie Flores, PT, MSPT, MA, PhD, Certified Lymphedema Therapist, is the Director of Cancer Rehabilitation for the Cancer Survivorship Institute at Robert H. Lurie Comprehensive Cancer Center of Northwestern University and has devoted her career to the reduction of physical and functional side effects from cancer and its treatment.

Her clinical research goals are to conduct and translate population-based research into patient-centered evidence-based interventions to prevent cancer-related limitations, impairments and disability particularly for minorities and the underserved and disseminate and implement interventions to define the standard of cancer rehabilitation care and delivery across health care systems. She has received grants from the National Cancer Institute, Foundation for Physical Therapy Research, Komen for the Cure/Susan G. Komen Foundation, Lynn Sage Foundation and others

She received her PT, MSPT degree from the University of Miami, and her MA and PhD degrees from The Ohio State University.




Frederick M. Howard, MD, is an Assistant Professor of Medicine in the section of Hematology/Oncology at the University of Chicago.

He received his medical degree from the University of Michigan and completed his residency and chief residency in Internal Medicine at Yale-New Haven Hospital in New Haven, Connecticut. Dr Howard cares for patients with breast cancer and head/neck cancer. His research focuses on the use of big data and artificial intelligence to improve care for cancer patients.

In 2024, Dr. Howard was named on the prestigious list of 40 Under 40 in Cancer, an award that recognizes him as one of the nation's most promising young oncology professionals and celebrates his contributions to improve the lives of those affected by cancer.



Speaker Biographies



Irene M. Kang, MD, is medical director of women’s health medical oncology and an assistant professor in the Department of Medical Oncology & Therapeutics Research, where she specializes in breast cancer. Her passion for oncology stems from the meaningful relationships she forms with patients and the hope for better outcomes. Her practice philosophy is that care is collaborative and personalized to a patient’s goals.

Dr. Kang is a Phi Beta Kappa graduate from the University of California Berkeley and earned her medical degree from the University of California San Francisco. She then completed a residency in internal medicine at Santa Clara Valley Medical Center and a fellowship in oncology/hematology at the University of Southern California. She was recruited to the faculty at USC, receiving a teaching award for her work with oncology fellows, and was ranked among LA’s “Top Doctors,” according to LA magazine. She joined City of Hope in 2022 and is the medical director of women’s health medical oncology at City of Hope Orange County.

Her research interests focus on molecular characterization of breast tumors and investigating new treatments for breast cancer. She is active in national organizations including the American Society of Clinical Oncology and the Southwest Oncology Group.



Melissa M. McShane, MD, is a medical oncologist at Fox Chase Cancer Center, and specializes in the treatment of breast cancer.

Dr. McShane received her medical degree from Sidney Kimmel Medical College, graduating cum laude. She completed her internal medicine residency at the University of Virginia Medical Center. She went on to complete her hematology/oncology fellowship at Fox Chase Cancer Center and held the role as Chief Fellow. After fellowship, Dr. McShane began her academic career at Fox Chase.

Dr. McShane has been recognized in *Philadelphia Magazine* Top Doctors. She is a member of the American Society of Hematology and the American Society of Clinical Oncology. In addition, she is a member of the NCCN Breast Cancer Panel.



Tuya Pal, MD, is Professor of Medicine and the Ingram Professor of Cancer Research at the Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center.

Dr. Pal earned her medical degree from McGill University in Montreal, Quebec. She completed a fellowship in clinical genetics at the Hospital for Sick Children/University of Toronto and a research fellowship in cancer genetics at the Women's College Research Institute, also located in Toronto.

Dr. Pal's clinical and research interests include inherited cancer risks across basic and clinical services, and health services delivery across populations. Her interests also a focus on alternative models to streamline and expand care delivery for individuals at-risk for inherited cancer across various settings, as well as interventions to improve follow-up care for those with inherited cancer. In addition to her research, Dr. Pal leads and manages the Inherited Cancer Registry (ICARE), a free cancer registry for those with inherited cancer predisposition interested in participating in research.

Dr. Pal is a member of numerous professional societies and committees, including the American College of Medical Genetics, the American Society of Clinical Oncology, and the American Association of Cancer Research.

Dr. Pal is Vice Chair of the NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate Cancer Panel and serves on the NCCN Biomarkers Resource Committee.



Speaker Biographies



Laura H. Rosenberger, MD, MS, is an Associate Professor of Surgery at Duke University School of Medicine, and surgical oncologist at Duke Cancer Institute.

Dr. Rosenberger is passionate about helping patients understand the complex and personal diagnosis of breast cancer. As a surgeon, she manages all types of breast cancer but specializes in phyllodes tumors, fibroadenoma and fibroepithelial lesions, and breast sarcomas.

Dr. Rosenberger received her medical degree from Thomas Jefferson University, Sidney Kimmel Medical College. She received her MS from University of Virginia. She completed her general surgery residency at University of Virginia School of Medicine, and her breast surgical oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Rosenberger is a member of the NCCN Breast Cancer Panel.



Wafa Samara, PharmD, is Vice President and Chief Pharmacy Officer at City of Hope National Medical Center in Duarte, CA.

As the pharmacist-in-charge, Dr. Samara is responsible for the strategic planning, business growth, oversight, and leadership of the pharmacy system and for ensuring the highest level of quality, safety, care and experience, and compliance across the United States.

Prior to joining City of Hope, Dr. Samara held multiple executive leadership positions, including Chief of Pharmacy Service at the National Institutes of Health (NIH), Chief of Pharmacy Service at the Department of Veterans Affairs (VA) and Chief Operating Officer at the VA.

In her current role as Chief Pharmacy Officer, Dr. Samara has been instrumental in closing the gap between cancer innovation and the people who have access to them. She positioned the pharmacy to be a strategic partner at the organizational and national levels through advocacy and by creating private public partnerships. She expanded the role of the pharmacists in oncology allowing top of the license practicing. She launched multiple programs to improve cancer health care delivery, safety, research, and patient experience. She continues her advocacy for diversity, equity, and inclusion in cancer care.

Dr. Samara is a member of The Alliance of Dedicated Cancer Centers (ADCC) leadership group, a board member of the California Society of Health System Pharmacists (CSHP) Hospital Council and a governing council for American Public Health Association.

Dr. Samara received her Doctor of Pharmacy degree from University of Florida after completing a bachelor's degree in pharmacy at the Hebrew University in Jerusalem and a residency at Hadassah Medical Center in Jerusalem. Dr. Samara completed multiple certifications, including Lean System Improvement and Patient Safety. As a certified transformational coach and mentor, she successfully launched APHA's pharmacy mentorship program that advances the pharmacy contribution in public health.

As a former United States Air Force honorary commander, Dr. Samara expanded the partnership between VA and Department of Defense (DOD). Over the years Dr. Samara received multiple awards for her contributions including multiple NIH and VA special contribution awards, US congressional commendation, 2024 health care woman of the year, and APHA lifetime achievement award.



Speaker Biographies




Melinda L. Telli, MD, is Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, the Director of the Breast Cancer Program and Associate Director for Clinical Research at the Stanford Cancer Institute, and Associate Director of the Stanford Women's Cancer Center.

Dr. Telli received her undergraduate degree from the University of Pennsylvania *magna cum laude* and her medical degree from George Washington University with distinction. She subsequently completed an internship and residency in internal medicine at Stanford University and stayed at Stanford to pursue fellowship training in medical oncology.

Dr. Telli's research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Her work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from DNA repair defect-targeted therapies. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she has also explored the use of 'beyond BRCA' DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.

Dr. Telli is a Fellow of the American Society of Clinical Oncology and member of the NCCN Breast Cancer Panel.



Kay T. Yeung, MD, PhD, is a board-certified medical oncologist who specializes in the treatment of breast cancer. She is an Associate Clinical Professor in the Division of Hematology-Oncology at UC San Diego Moores Cancer Center.

In addition to caring for patients, Dr. Yeung is a physician-scientist whose research focuses on breast cancer, including understanding the mechanism of breast tumor dormancy and investigating clinical prognostic value of molecular profiling of circulating tumor cells. Her work has been published in *Nature Cancer*, *Cancer Discovery*, *Nature Medicine*, *Clinical Cancer Research*, and others.

She also teaches medical school students, residents, and fellows at UC San Diego School of Medicine. Dr. Yeung was chief fellow during her hematology/oncology fellowship at UC San Diego School of Medicine, where she also completed her residency in internal medicine.

She earned her medical degree and a doctorate in pharmacology at New York University School of Medicine. She is board certified in internal medicine and medical oncology.

Dr. Yeung is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. She is a member of the NCCN Breast Cancer Panel.



Who We Are

An alliance of leading cancer centers devoted to patient care, research, and education

Our Mission

To define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives

Our Vision

Access to high-quality, high-value, patient-centered cancer care for all people globally

NCCN Member Institutions

Click [here](#) to view the full list of NCCN Member Institutions.

Learn More

[NCCN.org](https://www.nccn.org) – For Clinicians

[NCCN.org/patients](https://www.nccn.org/patients) – For Patients

[Education.nccn.org](https://www.education.nccn.org) – CE Portal

Continuing Education Activities

NCCN 2026 Annual Conference: [Click here](#)

NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care: [Click here](#)

NCCN Webinar Series – Optimizing Patient Outcomes: Collaborative Perspectives in Oncology: [Click here](#)